Senseonics/$SENS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Senseonics
Senseonics Holdings Inc is a medical technology company. It is focused on the design, development, and commercialization of glucose monitoring system, which helps people to manage their diabetes community with differentiated, long-term implantable glucose management technology. Its products and services include a Continuous glucose monitoring system, Sensor, Smart transmitter, and Mobile app. The firm has a Glucose monitoring product segment. The majority of the revenue is generated outside of the United States.
Ticker
$SENS
Sector
Primary listing
AMEX
Industry
Health Care Equipment and Supplies
Headquarters
Employees
117
Website
Senseonics Metrics
BasicAdvanced
$405M
-
-$0.11
1.06
-
Price and volume
Market cap
$405M
Beta
1.06
52-week high
$1.40
52-week low
$0.25
Average daily volume
7.6M
Financial strength
Current ratio
6.884
Quick ratio
6.198
Long term debt to equity
115.436
Total debt to equity
116.7
Interest coverage (TTM)
-8.97%
Profitability
EBITDA (TTM)
-68.408
Gross margin (TTM)
7.19%
Net profit margin (TTM)
-312.47%
Operating margin (TTM)
-296.00%
Revenue per employee (TTM)
$200,000
Management effectiveness
Return on assets (TTM)
-41.00%
Return on equity (TTM)
-161.19%
Valuation
Price to revenue (TTM)
13.874
Price to book
9.31
Price to tangible book (TTM)
9.31
Price to free cash flow (TTM)
-5.603
Free cash flow yield (TTM)
-17.85%
Free cash flow per share (TTM)
-0.089
Growth
Revenue change (TTM)
1.64%
Earnings per share change (TTM)
-16.38%
3-year revenue growth (CAGR)
21.18%
3-year earnings per share growth (CAGR)
-9.81%
What the Analysts think about Senseonics
Analyst ratings (Buy, Hold, Sell) for Senseonics stock.
Bulls say / Bears say
Senseonics received FDA approval for its Eversense 365 Continuous Glucose Monitoring (CGM) system and launched it in partnership with Ascensia, leading to a 56% increase in its global patient base in 2024. (stockhouse.com)
H.C. Wainwright raised its price target for Senseonics to $1.40, citing growth drivers such as the expected approval and launch of Eversense 365 in the EU and integration with Sequel Diabetes' twiist insulin delivery system. (investing.com)
Senseonics anticipates doubling its global patient base in 2025, projecting revenues between $34 million and $38 million, driven by the rollout of Eversense 365 to U.S. patients. (drugdeliverybusiness.com)
Senseonics reported a net loss of $15.5 million in Q4 2024, indicating ongoing financial challenges despite revenue growth. (drugdeliverybusiness.com)
The company announced a $50 million public offering of common stock, which could lead to shareholder dilution. (tradingview.com)
BTIG maintained a Neutral rating on Senseonics shares, expressing caution despite FDA clearance for the Eversense 365 CGM system. (investing.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
Senseonics Financial Performance
Revenues and expenses
Senseonics Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Senseonics stock?
Senseonics (SENS) has a market cap of $405M as of July 30, 2025.
What is the P/E ratio for Senseonics stock?
The price to earnings (P/E) ratio for Senseonics (SENS) stock is 0 as of July 30, 2025.
Does Senseonics stock pay dividends?
No, Senseonics (SENS) stock does not pay dividends to its shareholders as of July 30, 2025.
When is the next Senseonics dividend payment date?
Senseonics (SENS) stock does not pay dividends to its shareholders.
What is the beta indicator for Senseonics?
Senseonics (SENS) has a beta rating of 1.06. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.